Clinical trial
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
NCT00286455 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00286455 |
|---|---|
| Title | Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Alogliptin, Placebo |
| Enrollment | 329 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Feb 3, 2006 |
| Last update posted | Feb 3, 2012 |
| Countries | Argentina, Australia, Brazil, Chile, Czechia, Dominican Republic, Germany, Guatemala, Hungary, India, Mexico, Netherlands and 6 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: